Dr. Marco Mura, MD, PhD

Mura

Rank / Affiliations

  • Associate Professor of Medicine

Training

  • MD, University of Bologna, Italy
  • Respirology, University of Rome Tor Vergata, Rome, Italy
  • PhD, University of Bologna, University of Toronto
  • Fellowship, Lung Transplantation, University of Toronto
  • Fellowship, Pulmonary Hypertension, University of Toronto
  • Fellowship, Interstitial Lung Disease, University of Toronto

Clinical Interest

  • Interstitial lung disease
  • Pulmonary hypertension
  • Lung Transplantation

Research Interest

  • Molecular diagnosis of idiopathic interstitial pneumonias
  • Prognostic models in idiopathic pulmonary fibrosis

Research Funding

  • "Educational Grant, La Roche Canada (2020-2021) Transition of care for ILD/IPF patients candidates for lung transplant - an educational manual for patients."
  • Amoso Innovation Fund (2019-2021). “Molecular diagnosis of idiopathic interstitial pneumonias: a prospective study”
  • Department of Medicine Research Fund (2019-2021). “Validation of a new ,ulti-dimensional staging system in idiopathic pulmonary fibrosis”
  • Lawson Internal Research Fund (2019-20). “Immunohistochemistry and molecular markers of senescence as new diagnostic tools in idiopathic interstitial pneumonias”  
  • Educational Grant, La Roche Canada. Education in interstitial lung disease (2019-2020)
  • Ontario Respiratory Care Association (2018-2019). “Use of computed tomography to assess muscle mass in patients with interstitial lung disease at diagnosis and through disease progression: a retrospective pilot study” (co-recipient).
  • Western Strategic Support for CIHR Success, Seed Grant.2013 “Ascertainment of the best prognostic serum biomarker in idiopathic pulmonary fibrosis: a pilot study”
  • IPF Research Award, European Respiratory Society, 2013. "The risk of stratification score as a novel staging system for idiopathic pulmonary fibrosis"

Awards

  • David Bates Award for the Best Clinical Research Presentation, 17th Canadian Resident Fellow Competition in Respiratory Research, Canadian Thoracic Society, 2010
  • University Health Network/Mount Sinai Hospital Fellowship Award (Lawson Scholarship). Title of the project: “A gene expression profile based on pulmonary artery pressures in pulmonary fibrosis to identify distinct phenotypes of the disease and predict primary graft dysfunction after lung transplantation”, 2010
  • Entelligence Young Investigators Award (Actelion Pharmaceuticals). Title of the project: “Osteopontin in Idiopathic Pulmonary Arterial Hypertension, A Biomarker and Therapeutic Target”, 2011
  • IPF Research Award, European Respiratory Society, 2013. Title of the project: “The risk stratification score as a novel staging system for idiopathic pulmonary fibrosis”

 

Selected Publications (past 5 years)

Van Der Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Therapeutic Advances in Respiratory Disease 2022; 16: 1-16

 

Mura M, Rellini C, Taha N, Sbordone FP, Rufi F, Montesanto F, Floris R, Zompatori M, Sergiacomi G. Radiographic progression and survival of the different HRCT patterns of idiopathic pulmonary fibrosis. Sarcoidosis, Vasculitis and Diffuse Lung Disease 2022; 39: 32022021

 

Keow J, Cecchini M, Jayawardena N, Zompatori M, Joseph M, Mura M. Digital quantification of p16-positive foci in fibrotic interstitial lung disease identifies a senescent phenotype of idiopathic pulmonary fibrosis with reduced survival. Respiratory Research 2022: 23: 147

 

Kraven L, Taylor AR, Molyneaux PL, Maher TM, McDonough JE, Mura M, Yang IV, Shwartz DA, Huang Y, Noth I, Ma SF, Yeo AJ, Fahy WA, Jenkins RG, Wain LV. Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis. Thorax, published online May 9th, 2022

 

Manzetti GM, Hosein K, Cecchini M, Kwan K, Zompatori M, Rogliani P, Mura M. Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. BMC Pulmonary Medicine 2021; 21: 396

 

 

Mura M, Bouros D. Exercise testing in idiopathic pulmonary fibrosis: expanding our options. Respiration 2021; 100: 568-570

 

Rinaldi S, Balsillie C, Truchon C, Al-Mubarak A, Mura M, Madill J. Nutrition implications of intrinsic restrictive lung disease. Nutrition in Clinical Practice 2022; 37: 239-255

 

Zagà E, Abdelrazek M, Shalhoub S, Mura M. Invasive pulmonary aspergillosis in an immunocompetent, heavy smoker of marijuana with emphysema and COPD. Canadian Journal of Respiratory, Critical Care and Sleep Medicine 2021;5:400-403

Mura M, Bouros D. Exercise testing in idiopathic pulmonary fibrosis: expanding our options. Respiration, published online April 13th, 2021

 

Rinaldi S, Gilliland J, O’Connor C, Seabrook JA, Mura M, Madill J. Exercise capacity and its relationship with body composition and nutrition status in patients with interstitial lung disease. Nutrition in Clinical Practice, published online, March 31st, 2021

 

Rinaldi S, Gilliland J, O’Connor C, Seabrook JA, Mura M, Madill J. Fat-free mass index controlled for age and sex, and malnutrition are predictors of survival in interstitial lung disease. Respiration, 2021 Mar 15:1-8

 

Zagà V, Dell’Omo M, Murgia N, Mura M. Tobacco worker’s lung: a neglected subtype of hypersensitivity pneumonitis. Lung 2021; 199: 13-19

 

Taha N, Hosein K, Grant-Orser A, Lin-Shaw A, Mura M. TPMT and HLA-DQA1-HLA-DRB genetic profiling to guide the use of azathioprine in the treatment of interstitial lung disease: first experience. Pulmonary Pharmacology and Therapeutics 2021; 66: 101988

 

Mura M. Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted. Pulmonary Pharmacology and Therapeutics 2021; 66: 101987 

 

Zagà E, Abdelrazek M, Shalhoub S, Mura M. Invasive pulmonary aspergillosis in an immunocompetent, heavy smoker of marijuana with emphysema and COPD. Canadian Journal of Respiratory, Critical Care and Sleep Medicine, published online, August 7th, 2020

 

Taha N, D'Amato D, Hosein K, Ranalli T, Sergiacomi G, Zompatori M, Mura M. Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters? Respiratory Research 2020; 21: 119

 

Hosein K, Sergiacomi G, Zompatori M, Mura M. The CALIPER-revised version of the Composite Physiologic Index is a better predictor of survival in IPF than the original version. Lung 2020; 198: 169-172

Mura M, Cecchini MJ, Joseph M, Granton JT. Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension. Respirology 2019; 24: 1104-1110 

 

Mura M, Juvet S. Bronchiolitis obliterans syndrome as manifestation of lung GVHD: Not the only one. Respirology 2019; 24: 702

 

Povitz M, Li L, Hosein K, Shariff S, Mura M. Implementing an interstitial lung disease clinic improves survival without increasing health care resource utilization. Pulmonary Pharmacology and Therapeutics 2019; 56: 94-99

 

Cecchini M, Hosein K, Howett C, Joseph M, Mura M.Comprehensive gene expression profiling of non-specific interstitial pneumonia and idiopathic pulmonary fibrosis identifies distinct and overlapping transcriptional profiles. Respiratory Research 2018Aug 15; 19: 153

 

Serajeddini H, Rogliani P, Mura M. Multi-dimensional assessment of idiopathic pulmonary fibrosis across a wide range of disease severity. Lung 2018; 196: 707-713

 

Yoo D, Zompatori M, Barrile A, Rossi G, Sergiacomi S, Rogliani P, Mura M. Associated pulmonary arterial hypertension is an independent contributor to exercise intolerance in chronic fibrotic interstitial pneumonias. Respiration, in press.

 

Moran-Mendoza O, Mura M, McCormack D, Poletti V, Tomassetti S, Fruchter O, Kramer M, Colby T, Wells AU. Letter. Regarding the “Evaluation of patients with fibrotic interstitial lung disease: a Canadian Thoracic Society position statement”. Canadian Journal of Respiratory, Critical Care and Sleep Medicine. Published online, March 27th, 2018.

 

Fisher J, AlHejaili F, Kendel S, Hirji A, Shapera S, Mura M. Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment. Respiratory Medicine 2017; 125: 65-71

 

Rinaldi S, Mura M, Madill J. Interstitial lung disease, body mass index, energy expenditure and malnutrition - a review. Current Pulmonology Reports, 2017; 6:70-74

 

Hosein K, Le J, Mura M. Assessing the therapeutic response to pirfenidone in patients with idiopathic pulmonary fibrosis: can we do better than with forced vital capacity alone? Lung 2017; 195: 101-105

 

Khadawardi H, Mura M. A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease. Respirology 2017; 22: 501-507

 

 

Contact Information

London Health Sciences Centre - Victoria Hospital

Phone: 519-667-6744 

Fax 519-685-8406